Sep 2026· European Journal of Nuclear Medicine and Molecular Imaging· Vol 53, pp. 8610 - 8620· 0 citations· 24 references
Medicine
TL;DR
Tri-modal fusion was superior to MRI-US fusion biopsy in detecting csPCa, particularly in small PSMA-positive and PI-RADS 4 lesions, and multicenter validation before clinical adoption.
Abstract
Multiparametric MRI (mpMRI)-ultrasound (US) fusion biopsy misses 8%-20% of clinically significant prostate cancer (csPCa), leaving a detection gap that prostate-specific membrane antigen (PSMA) PET/CT may help close. Whether incorporating PSMA into an MRI-US fusion platform improves csPCa detection has not been evaluated in a prospective paired design. We compared tri-modal PSMA PET/CT-MRI-US fusion biopsy with MRI-US fusion biopsy and systematic biopsy. In this prospective, single-center, and paired diagnostic accuracy study (STARD 2015; ChiCTR2400089436), 308 biopsy-naive men underwent tri-modal fusion biopsy, MRI-US fusion biopsy, and systematic biopsy in a single session. The primary endpoint was the absolute difference in patient-level csPCa detection (International Society of Urological Pathology grade group ≥ 2) between tri-modal and MRI-US fusion biopsies. Tri-modal fusion detected 4.9% more csPCa than MRI-US fusion biopsy (95% confidence interval 2.4%-7.3%; P < 0.001; number needed to biopsy 20.5). The most significant gains were observed for PSMA-positive lesions < 10 mm (8.3%) and Prostate Imaging Reporting and Data System (PI-RADS) 4 lesions (5.8%), and this benefit persisted in multivariate generalized estimating equation models. The PSMA imaging-based risk score (area under the curve, 0.933) showed higher discrimination than the PRIMARY and molecular imaging PSMA scores. In a retrospective simulation using the test set, a risk-guided approach would have avoided approximately 42% of biopsies while missing 2.3% of csPCa. Limitations include the single-center design and the small test set. Tri-modal fusion was superior to MRI-US fusion biopsy in detecting csPCa, particularly in small PSMA-positive and PI-RADS 4 lesions. A PSMA-derived risk score enabled effective stratification, and in the test set, a simulated risk-guided approach showed potential for biopsy reduction. These findings require multicenter validation before clinical adoption. ChiCTR2400089436 (Chinese Clinical Trial Registry, http://www.chictr.org.cn/, registered 2024-09-09).
OBJECTIVES
To compare the segment-based diagnostic performance of multiparametric magnetic resonance imaging (mpMRI), Gallium-68-prostate-specific membrane antigen-positron emission tomography/computed tomography (68Ga-PSMA-PET/CT), for detecting histopathologically confirmed prostate cancer (PCa).
PATIENTS AND METHO...
C. J. Schmidt, M. Bernhardt, Glen Kristiansen et al.· BJU International· 0 citations
Background/Objectives: Multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy has become central to prostate cancer (PCa) diagnosis. While cognitive and software-based fusion targeting have already been compared, the use of high-resolution micro-ultrasound as a real-time guidance platform for cognitive tran...
Agostino Fraia, S. Riolo, F. Di Bello et al.· Journal of Clinical Medicine· 0 citations
PURPOSE
Equivocal Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions carry an intermediate risk of clinically significant prostate cancer (csPCa). We evaluated the diagnostic value of prostate-specific membrane antigen positron emission tomography/magnetic resonance imaging (PSMA PET/MRI) with [18F...
R. Diamand, C. Artigas, A. Peltier et al.· Journal of Urology· 0 citations
To evaluate whether restricting systematic biopsy to the ipsilateral side of a unilateral multiparametric magnetic resonance imaging (mpMRI) lesion, in combination with cognitive MRI-targeted biopsy, affects the detection of clinically significant prostate cancer (csPCa) in biopsy-naïve patients.
This retr...
G. Tsakaldimis, D. Diamantidis, Nikolaos Smyrlis et al.· BMC Urology· 0 citations
Background: The incremental value of PSMA PET/CT over multiparametric MRI (mpMRI) for selecting patients for prostate cancer focal therapy is undefined. Unlike lesion-detection studies, we evaluated whether PSMA PET/CT, mpMRI, and their combination correctly determine focal therapy eligibility when validated against wh...
I. Sonni, Zahra Mohammadigoldar, G. Furey et al.· medRxiv· 0 citations
Prostate cancer (PCa) is the second most commonly diagnosed malignancy in men worldwide. Accurate pre-biopsy characterization of prostatic lesions remains a clinical challenge. Multiparametric magnetic resonance imaging (mpMRI), interpreted using Prostate Imaging-Reporting and Data System (PI-RADS) v2.1, has emerge...
A. Deshmukh, Krushna Chandra Biswal, Sangram Panda et al.· Journal of Integrative Medic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.